电话:
400-7060-959
传真:
+86 10 56315212-8813
电子邮件:
orders@antibodies-online.cn

Recombinant IL2RA (Basiliximab Biosimilar) 抗体

适用: 人 FACS, IF, IHC, WB, BR 宿主: 小鼠 Chimeric unconjugated Recombinant Antibody
产品编号 ABIN7487733
发货至: 中国
  • 抗原 See all IL2RA (Basiliximab Biosimilar) products
    IL2RA (Basiliximab Biosimilar)
    抗体类型
    Recombinant Antibody
    适用
    • 5
    • 2
    • 2
    宿主
    • 2
    • 2
    • 1
    小鼠
    克隆类型
    • 3
    • 2
    Chimeric
    标记
    • 5
    This IL2RA (Basiliximab Biosimilar) antibody is un-conjugated
    应用范围
    • 5
    • 3
    • 3
    • 3
    • 2
    • 1
    • 1
    Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB), Blocking Reagent (BR)
    交叉反应
    Cynomolgus, 猕猴
    产品特性

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    纯化方法
    Purified antibody.
    免疫原
    Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.
    亚型
    IgG1 kappa
  • 应用备注
    Optimal working dilution should be determined by the investigator.
    说明

    NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques.

    限制
    仅限研究用
  • 缓冲液
    PBS with 0.02 % Proclin 300.
    储存液
    ProClin
    注意事项
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    储存条件
    4 °C,-20 °C
    储存方法
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • 抗原
    IL2RA (Basiliximab Biosimilar)
    Abstract
    IL2RA (Basiliximab Biosimilar) 产品
    别名
    CD25 antibody, IDDM10 antibody, IL2R antibody, TCGFR antibody, IL2RAC antibody, Il2r antibody, Ly-43 antibody, interleukin 2 receptor subunit alpha antibody, interleukin 2 receptor, alpha chain antibody, IL2RA antibody, Il2ra antibody
    背景
    Interleukin-2 receptor subunit alpha, IL-2 receptor subunit alpha, IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD25.
    UniProt
    P01589
You are here: